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Abstract 
Background: Thrombocytopenia is a frequent finding in critically ill cancer patients for whom indications of platelet 
transfusions are unclear. We herein addressed the current practices in platelet transfusion and the risk of bleeding in 
cancer patients with hypoproliferative thrombocytopenia in the intensive care unit (ICU).
Methods: A retrospective monocenter study over a 7‑year period was conducted in a medical ICU. Adult patients 
with malignancies and hypoproliferative thrombocytopenia, and who received at least one platelet concentrate dur‑
ing their ICU stay, were included.
Results: 296 patients were included and received a total of 904 platelet transfusions, for prophylactic indications in 
300 (33.2 %) episodes, for securing an invasive procedure in 257 (28.4 %), and for treatment of minor to major bleed‑
ing manifestations in 347 (38.4 %). Most prophylactic transfusions (80 %) were performed at platelet count thresholds 
below 10–20 × 109/L. Platelet increments were generally low in all three indications, 10 (interquartile range 2–25), 11 
(2–25), and 8 (0–21) × 109/L, respectively. A total of 97 major ICU‑acquired bleeding events occurred in 40 patients. 
About half of those bleeding episodes (54.7 %) occurred at platelet counts below 20 × 109/L. However, neither low 
admission platelet count nor low nadir platelet counts were predictive of ICU‑acquired bleeding. The in‑ICU mortality 
rate tended to be higher in patients with severe ICU‑acquired bleeding events (50 vs. 36 %).
Conclusions: Most prophylactic platelet transfusions were given using thresholds of 10–20 × 109/L in critically ill 
thrombocytopenic cancer patients. The individual risk of ICU‑acquired severe bleeding appears hardly predictable 
with the depth of thrombocytopenia.
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Background
Thrombocytopenia is a frequent finding in critically ill 
patients, either present at the time of intensive care unit 
(ICU) admission or further acquired during the ICU stay 
[1]. Thrombocytopenia carries major implications in 
terms of diagnostic investigations, prognosis, and specific 
treatment with particular emphasis on platelet transfu-
sions. The mechanisms leading to thrombocytopenia in 
the critically ill are mostly peripheral through consump-
tion or destruction [2]. The poor prognostic value of 
thrombocytopenia has been largely emphasized in the 
ICU. Most interestingly, it has been shown that relative 
thrombocytopenia, as defined by a 30 % drop in platelet 
count regardless of baseline and final values, shares simi-
lar pathophysiological and prognostic significance with 
absolute thrombocytopenia [3, 4]. This suggests that the 
process leading to platelet consumption is more impor-
tant than the platelet count by itself. With respect to the 
risk of bleeding, it is striking that the risk of bleeding in 
ICU patients is poorly related to the depth of thrombocy-
topenia [2, 4, 5]. However, such studies were performed 
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in cohorts of critically ill patients in whom peripheral 
mechanisms leading to thrombocytopenia were largely 
predominant [2, 5]. In contrast, a number of ICU criti-
cally ill patients primarily exhibit decreased platelet 
production as a consequence of underlying malignant 
diseases and their myelosuppressive treatments. The rela-
tion between platelet count and bleeding in this setting 
has not been addressed.
The only goal of platelet transfusions is to prevent or to 
treat bleeding. To this day, indications of platelet trans-
fusions in the ICU remain highly speculative. Recently, 
the French Intensive Care Society provided some expert 
recommendations guiding platelet transfusions in the 
ICU [6]. The platelet count threshold for securing inva-
sive procedures or treating severe bleeding was set at 
50  ×  109/L. As for prophylactic platelet transfusions, 
the guidelines did not retain any indication in patients 
with peripheral thrombocytopenia and proposed a plate-
let count threshold of 20  ×  109/L for hypoproliferative 
thrombocytopenia. Of note, such a restrictive transfusion 
policy was only based on studies performed in hemato-
logic patients in stable conditions and may not apply to 
critically ill patients. We herein aimed to address the 
current practices in platelet transfusion and the risk of 
bleeding in cancer patients with hypoproliferative throm-
bocytopenia in a medical intensive care unit.
Patients and methods
Patients and setting
This retrospective observational study was carried out 
over a 7-year period (December 2006 to February 2014) 
in a 24-bed tertiary medical ICU. The unit is located in a 
university hospital that comprises hematology and oncol-
ogy departments, and has an average of 1600 admissions 
per year, with a large majority (>85 %) of medical patients. 
Adult patients with hematologic malignancies or solid 
tumors with presumed or proved central thrombocytope-
nia as defined by a platelet count below 150 × 109/L, and 
who received at least one platelet concentrate during the 
ICU stay, were included. Patients with thrombocytopenia 
from exclusive peripheral origin were not included. Senior 
staffing of the unit remained unchanged during the study 
period. The study was conducted in compliance with the 
Declaration of Helsinki principles and with the French 
regulation of clinical research. The ethics committee of the 
French Intensive Care Society (Société de Réanimation de 
Langue Française, CE SRLF #15-17) approved the protocol 
and waived the need for patients’ consent because of the 
retrospective observational design of the study.
Collection of data
Data were computed from medical files and extracted 
from the patient data management system (CliniSoft, 
GE Healthcare). For each patient, the following baseline 
data were collected: demographics (age and gender), type 
of malignancy (solid tumor or hematologic malignancy), 
and the presence of other comorbidities such as chronic 
organ dysfunctions. The presumed or proved mecha-
nisms of central thrombocytopenia were also collected.
The characteristics related to the ICU stay were col-
lected and included the main reasons for ICU admission, 
the main biological values on admission such as plate-
let count and leukopenia that was defined by leukocyte 
count <1000/mm3 and the requirements for organ failure 
supports during the stay in the ICU. Severity at admis-
sion was assessed by Simplified Acute Physiology Score 
II (SAPS II) and Sequential Organ Failure Assessment 
(SOFA) score during the first 24 h following ICU admis-
sion [7, 8]. We also calculated a modified SOFA score 
without the platelet component.
Definitions of bleeding events
Bleeding events were recorded and graded from 0 to 4 
according to the World Health Organization (WHO) 
classification [6, 9]. Briefly, grades 0 and 1 meant no or 
minor bleeding, respectively. Grade 2 accounted for mild 
bleeding yet requiring medical intervention but no trans-
fusion of red blood cell (RBC) concentrates. Grade 3 
accounted for gross blood loss responsible for advent or 
deterioration of organ failures and/or requiring transfu-
sion of up to two RBC concentrates within 24 h of onset. 
Grade 4 accounted for debilitating blood loss including 
central nervous system or retinal hemorrhages, massive 
bleeding requiring transfusion of more than two RBC 
concentrates within 24  h of onset, and more generally 
fatal bleeding from any source. Major bleeding events 
were defined as WHO grade 3 and 4.
Intended management of platelet transfusions
Platelet transfusions were performed using ABO-com-
patible and leukodepleted concentrates, prepared either 
from pooled whole-blood donations or from single 
donor apheresis. The respective indications of pooled 
and apheresis concentrates depended on the clinical situ-
ation, an eventual anti-HLA immunization or the avail-
ability of blood products. Platelet dose per transfusion 
was calculated according to body weight (0.5–0.7 × 1011 
platelets per 7 kg body weight) [6, 10].
Indications of platelet transfusions were distributed 
into the three following categories: prophylactic, secur-
ing an invasive procedure, and therapeutic. Prophylactic 
transfusions aimed at maintaining platelet count above 
10–20  ×  109/L. Transfusions to secure invasive proce-
dures were performed before, during, or after the inter-
vention, without systematic subsequent checking for an 
effective increment in platelet count. Therapeutic platelet 
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transfusion was performed in case of active bleeding. 
For each platelet transfusion, pre- and post-transfusion 
platelet counts were computed from the last value prior 
to the transfusion and from the subsequent morning 
value, respectively. Platelet increment was estimated by 
calculating the absolute difference between post- and 
pre-transfusion platelet counts. We investigated the seri-
ous adverse events attributable to platelet transfusion as 
mentioned in the medical files and/or through reporting 
to our hospital’s hemovigilance.
Statistical analysis
Continuous and categorical variables were expressed as 
median and interquartile range or as number and per-
centage, respectively. Comparisons were performed by 




During the 7-year study period, 684 patients from our 
ICU received at least one platelet transfusion. Among 
them, 296 patients had hypoproliferative thrombocyto-
penia in the setting of malignancy and received a total of 
904 platelet transfusions. Their baseline characteristics 
are shown in Table 1. Most patients (81.7 %) had underly-
ing hematologic malignancies, of whom 42 (17.3 %) were 
hematopoietic stem cell transplantation recipients. The 
median platelet count at the time of ICU admission was 
29 (15–54) ×  109/L and the nadir platelet count during 
the ICU stay was 12 (6–23)  ×  109/L. According to the 
clinical background of patients, central thrombocytope-
nia was presumably related to myelosuppressive chemo-
therapy and/or radiotherapy in most cases. In addition, 
bone marrow explorations resulted in identification of 
alternative mechanisms of bone marrow suppression in 
73 (24.5  %) patients. As expected, a number of patients 
also displayed leukopenia. The main cause of admission 
to the ICU was sepsis in 139 (47  %) patients, while 17 
(5.7  %) were admitted for major hemorrhage (Table  2). 
Patients generally presented with severe conditions as 
shown by admission severity scores as well as frequent 
requirement of organ failure supports during the ICU 
stay. The in-ICU mortality rate was 37.8 %.
Indications for platelet transfusions
Indications for the 904 platelet transfusions were distrib-
uted into prophylactic in 300 (33.2 %) episodes, securing 
an invasive procedure in 257 (28.4 %) episodes, mainly for 
catheter insertion (42.3 %) and surgery (27 %), and thera-
peutic for minor to major bleeding manifestations in 347 
(38.4  %) episodes. Grade 1, 2, 3, and 4 bleeding events 
accounted for 12, 135, 132, and 68 episodes of therapeu-
tic platelet transfusions, respectively. Figure 1 represents 
the distribution of platelet transfusions according to 
pre-transfusion platelet count in those three indications. 
Most prophylactic transfusions (80  %) were performed 
when platelet counts were below 20  ×  109/L. Figure  2 
displays platelet recovery as estimated by pre- and post-
transfusion platelet counts and the resulting platelet 
count increment in the three indications of platelet trans-
fusions. Platelet transfusions were generally well toler-
ated as only five serious adverse events were reported, all 
being immediate respiratory deterioration presumably 
related to volume overload.
Table 1 Baseline characteristics of patients
Variables are expressed as median (interquartile range) or number (percentage)
Variables 296 patients
Age (years) 62 (53–70)
Male gender 196 (66 %)
Underlying malignancies
 Hematologic malignancies 242 (81.7 %)
  Acute leukemia 99 (33.4 %)
  Lymphoma 96 (32.4 %)
  Multiple myeloma 28 (9.4 %)
  Miscellaneous 19 (6.4 %)
 Solid tumors 54 (18.3 %)
  Uro‑genital 17 (5.7 %)
  Digestive 15 (5 %)
  Pulmonary 9 (3 %)
  Breast 6 (2 %)
  Bone and cartilage 4 (1.3 %)
  Head and neck 4 (1.3 %)
Hematopoietic stem cell transplantation 42 (14.2 %)
Other comorbidities
 Chronic heart failure 61 (20.6 %)
 Chronic liver disease 13 (4.4 %)
 Chronic and end‑stage renal failure 13 (4.4 %)
 Human immunodeficiency virus infection 6 (2 %)
 Solid organ transplantation 1 (0.3 %)
Anticoagulant and antiplatelet medications 69 (23.3 %)
 Prophylactic anticoagulant 21 (7.1 %)
 Curative anticoagulant 27 (9.1 %)
 Antiplatelet 21 (7.1 %)
Mechanisms of central thrombocytopenia
 Chemo‑ or radiotherapy‑induced 223 (75.3 %)
 Bone marrow infiltration by malignant cells 55 (18.5 %)
 Hemophagocytosis 10 (3.4 %)
 Drug‑induced (allergic) 4 (1.3 %)
 Myelofibrosis 4 (1.3 %)
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ICU‑acquired major bleeding events
Seventeen patients who had been primarily admitted 
for severe hemorrhage were excluded from the follow-
ing analysis regarding ICU-acquired bleeding. Among 
the remaining 279 patients, a total of 97 WHO grade 3 
and 4 bleeding events occurred in 40 patients (Table 3). 
About half of severe bleeding episodes (54.7 %) occurred 
in the setting of profound thrombocytopenia with plate-
let counts below 20 × 109/L. Concurrent therapeutic and 
prophylactic anticoagulant or antiplatelet agents were 
likely to have contributed to bleeding in only 8.2  % of 
episodes. In an attempt to identify some determinants 
of ICU-acquired severe bleeding, we compared the main 
characteristics of patients who did and did not develop 
severe bleeding during the ICU stay (Table  4). Patients 
who developed severe bleeding were more likely to be 
leukopenic, and both admission and nadir platelet counts 
were higher in patients who bled. ICU-acquired severe 
bleeding tended to be associated with increased in-ICU 
mortality (50 vs. 36 %).
Discussion
A number of studies have underscored the high preva-
lence and the poor prognostic value of thrombocyto-
penia in the ICU [1–3, 5, 6, 11–15]. Beyond absolute 
thrombocytopenia, decline in platelet count over the first 
days in the ICU, the so-called relative thrombocytope-
nia, also represents a reliable prognostic factor in addi-
tion to single measurements [2, 3, 11]. This suggests that 
the prognostic value of thrombocytopenia might not only 
be fully related to its depth, but also to the underlying 
pathophysiological process leading to platelet consump-
tion or destruction [16]. It is noteworthy that all studies 
about thrombocytopenia in the ICU and the eventual 
indication of platelet transfusions have been performed 
in general cohorts of patients for whom decrease in plate-
let counts was mainly related to peripheral mechanisms 
[2–5, 17]. To the best of our knowledge, this is the first 
study that specifically addresses the transfusion manage-
ment in cancer patients with hypoproliferative thrombo-
cytopenia in the ICU.
The risk of bleeding events in the setting of thrombo-
cytopenia underlies the use of prophylactic platelet trans-
fusions. The current guidelines about the management 
of platelet transfusions in hypoproliferative thrombocy-
topenia are mainly derived from studies in patients with 
hematological malignancies requiring chemotherapy 
or undergoing allogeneic or autologous hematopoietic 
stem cell transplantation [18, 19]. Studies in hematol-
ogy have been able to correlate the nadir platelet count 
with bleeding, the risk of severe hemorrhage clearly 
becoming much higher when platelet count drops below 
10 × 109/L [20–22]. In addition, various associated con-
ditions are likely to increase the risk not only of bleed-
ing in oncologic and hematologic thrombocytopenic 
patients, including the duration of thrombocytopenia, 
but also altered functional status, bone marrow metas-
tasis, allogeneic bone marrow transplantation, a recent 
history of bleeding, hypoalbuminemia, and treatment 
with drugs affecting platelet function [21, 23]. Over the 
last two decades, several studies have addressed the indi-
cations of prophylactic platelet transfusion in clinically 
stable patients without active bleeding. Compared to the 
once traditional trigger of 20 × 109/L, these studies have 
proven the safety and the cost-effectiveness of a more 
restrictive trigger of 10  ×  109/L in patients with pro-
longed thrombocytopenia related to acute myeloid leuke-
mia [24–27]. An exclusive therapeutic policy was recently 
proposed to restrict platelet transfusion to documented 
bleeding [22, 28]. However, such a restrictive transfusion 
Table 2 Characteristics of ICU admission and management 
of organ failures
Variables are expressed as median (interquartile range) or number (percentage). 
The modified SOFA score did not include the platelet component
ICU intensive care unit, SAPS II simplified acute physiology score II, SOFA 
sequential organ failure assessment score
Variables 296 patients
Reasons for ICU admission
 Sepsis 139 (47 %)
 Acute respiratory failure 67 (22.6 %)
 Severe hemorrhage 17 (5.7 %)
 Acute renal failure 16 (5.4 %)
 Others 57 (19.2 %)
Admission severity scores
 SAPS II (points) 51 (36–69)
 SOFA (points) 7 (5–10)
 Modified SOFA (points) 4 (2–7)
Admission biological values
 Platelet count (×109/L) 29 (15–54)
 Leukopenia 117 (39.5 %)
 Prothrombin time (%) 65 (51–77)
 Serum urea (mmol/L) 10 (6.8–17.8)
 Serum creatinine (μmol/L) 108 (72–184)
 Serum bilirubin (μmol/L) 19 (11–42)
Organ failure supports during ICU stay
 Non‑invasive ventilation 120 (40.5 %)
 Invasive mechanical ventilation 181 (61.1 %)
 Vasopressors 187 (63.2 %)
 Renal replacement therapy 120 (40.5 %)
Platelet transfusion management
 Nadir platelet count during ICU stay (109/L) 12 (6–23)
 Total number of platelet transfusions 2 (1–4)
In‑ICU length of stay (days) 5 (2.3–13.2)
In‑ICU mortality 112 (37.8 %)
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policy was associated with an increased risk of moderate-
to-severe bleeding in patients with prolonged and pro-
found thrombocytopenia as seen in acute leukemia.
The French Intensive Care Society recently provided 
expert recommendations in the management of platelet 
transfusions in the ICU [6]. Prophylactic platelet trans-
fusion was recommended for central thrombocytopenia 
when platelet count fell below 20 ×  109/L. Accordingly, 
the large majority (80  %) of prophylactic platelet trans-
fusions in the present study were performed at plate-
let counts thresholds lower than 20  ×  109/L. However, 
this recommendation was derived from studies per-
formed in hematologic patients in stable conditions, 
and whether it can be safely implemented in critically 
Fig. 1 Distribution of pre‑transfusion platelet counts for the three indications of transfusion: prophylactic (n = 300), securing an invasive procedure 
(n = 257) and therapeutic (n = 347)
Fig. 2 Platelet count recovery according to indications for platelet 
transfusions
Table 3 Characteristics of  the 97 ICU-acquired severe 
bleeding events in 40 patients
Variables are expressed as median (interquartile range) or number (percentage)
ICU intensive care unit, WHO World Health Organization
Variable ICU‑acquired severe 
bleeding events (n = 97)
WHO bleeding classification
 Grade 3 64 (66 %)
 Grade 4 33 (34 %)
Timing of bleeding
 Time between admission and bleeding (days) 4 (1–9.5)
Sites of bleeding
 Digestive 32 (33 %)
 Pulmonary 22 (22.7 %)
 Site of invasive procedure 13 (13.4 %)
 Central nervous system 5 (5.1 %)
 Urinary 8 (8.2 %)
 Others 17 (17.5 %)
Platelet count at the time of bleeding (×109/L)
 ≤10 18 (18.6 %)
 11–20 35 (36.1 %)
 21–50 37 (38.1 %)
 51–100 7 (7.2 %)
Urea level at the time of bleeding (mmol/L) 13.7 (9.1–19.8)
Prothrombin time at the time of bleeding (%) 56 (43.5–70.2)
Concurrent anticoagulant and/or antiplatelet 
treatment
8 (8.2 %)
 Preventive anticoagulant treatment 5 (5.1 %)
 Curative anticoagulant treatment 2 (2.1 %)
 Antiplatelet agent 2 (2.1 %)
 Activated protein C 1 (1 %)
Page 6 of 8Habr et al. Ann. Intensive Care  (2015) 5:46 
ill cancer patients had not been addressed previously. 
Indeed, the quantitative relation between platelet count 
and hemorrhage remains unclear in critically ill patients 
in contrast to thrombocytopenic patients in stable con-
ditions. Observational studies retrieved an increased risk 
of bleeding for severe thrombocytopenia (platelet count 
<50 × 109/L), whereas the risk associated with moderate 
(50–100  ×  109/L) and mild (100–150  ×  109/L) throm-
bocytopenia was inconsistent [2, 4, 5, 13, 29]. Whether 
thrombocytopenia was directly involved in bleeding 
through the nadir platelet count or indirectly as a marker 
of severity remains unclear. Altogether, these results and 
ours suggest that ICU-acquired severe bleeding is a mul-
tifactorial process that is not only dependent on a sole 
platelet count. Most importantly, some additional fac-
tors such as uremia, other coagulation disorders, or anti-
coagulant treatments are frequently associated with the 
development of bleeding in the ICU, and should certainly 
be taken into account in the decision-making process of 
platelet transfusion in thrombocytopenic patients [12, 
21].
A major obstacle to broad platelet transfusion lies in 
the limited availability of platelet concentrates. In addi-
tion, platelet transfusion may not be innocuous in the 
critically ill as supply of exogenous platelets may sustain 
or even exacerbate some pathophysiological thrombotic 
processes [15, 30–32]. Therefore, prophylactic platelet 
transfusion is usually not recommended in patients with 
Table 4 Comparisons between  patients with  and without  ICU-acquired severe bleeding (n =  279, after  excluding 17 
patients with bleeding on admission)
Variables are expressed as median (interquartile range) or number (percentage). The modified SOFA score did not include the platelet component
ICU intensive care unit, SAPS II simplified acute physiology score II, SOFA sequential organ failure assessment score
a The nadir platelet count was the lowest platelet count recorded prior to the first severe bleeding event, or during the whole ICU stay for patients without severe 
bleeding
Variable ICU‑acquired severe bleeding
n = 40 patients
No ICU‑acquired severe bleeding
n = 239 patients
p
Age 66.5 (57.2–73) 62 (54–69) 0.61
Male gender (%) 27 (67.5 %) 156 (65.3 %) 0.86
Underlying malignancy 1
 Hematologic malignancy 33 (82.5 %) 196 (82 %)
 Solid tumor 7 (17.5 %) 43 (18 %)
Bone marrow transplantation 5 (12.5 %) 34 (14.2 %) 0.87
Reasons for ICU admission
 Sepsis 15 (37.5 %) 124 (51.9 %) 0.12
 Others 25 (62.5 %) 115 (48.1 %) 0.12
Anticoagulant and/or antiplatelet treatment 8 (20 %) 57 (23.8 %) 0.69
Admission severity scores
 SAPS II (points) 69 (34.2–80) 51 (37–57) 0.57
 SOFA (points) 8 (6–11) 7 (5–10.7) 0.32
 Modified SOFA (points) 7 (3–8) 4 (1–7) 0.31
Admission biological values
 Platelet count (×109/L) 50 (26–84) 26 (13–53) <0.001
 Leukopenia 31 (77.5 %) 133 (55.6 %) 0.009
 Bilirubin (μmol/L) 21 (11–77.7) 19 (11–40.7) 0.36
 Serum urea (mmol/L) 10.9 (7.4–16.5) 9.7 (6.8–18.6) 0.20
 Prothrombin time (%) 62 (44–75) 65 (50.2–77) 0.41
Organ failures during ICU stay
 Nadir platelet count (×109/L)a 15 (7–27) 10 (6–19) 0.014
 Organ failure supports
  Renal replacement therapy 17 (42.5 %) 100 (42 %) 1
  Non‑invasive ventilation 15 (37.5 %) 102 (42.7 %) 0.60
  Invasive ventilation 28 (70 %) 139 (58.2 %) 0.16
  Vasopressors 30 (75 %) 152 (63.6 %) 0.21
In‑ICU mortality 20 (50 %) 86 (36 %) 0.11
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exclusive peripheral thrombocytopenia [6]. As men-
tioned above, it is likely that both central and peripheral 
mechanisms are involved in thrombocytopenia of cancer 
patients, who commonly exhibit risk factors for platelet 
transfusion refractoriness such as spleen enlargement, 
bleeding, fever, infection, disseminated intravascular 
coagulation as well as the number of previous transfu-
sions [33]. The low platelet recovery we observed in all 
three indications of transfusions probably resulted from 
fast consumption or destruction of exogenous platelets.
This study has several limitations. It was performed in 
a single tertiary care center with a particular case-mix of 
patients, and the period of inclusion was 7 years. How-
ever, our transfusion practices, based on previous stud-
ies in hematology and confirmed by the release of expert 
recommendations for critically ill patients, remained 
similar over the study period. Despite the fact that we 
primarily selected patients on the occurrence of plate-
let transfusions, this represents our common attitude in 
profound hypoproliferative thrombocytopenia and this 
probably allowed an exhaustive identification of patients. 
The major limit of the study obviously lies in its retro-
spective design, the results being highly dependent on 
the quality of records in the medical charts. However, we 
believe that automated extraction and quantitative vari-
ables from computerized charts as well as manual inquiry 
for other qualitative variable allowed us to perform a reli-
able collection of data. In contrast, duration, depth, and 
management of thrombocytopenia prior to ICU admis-
sion could not be accurately collected. The retrospective 
design may also have prevented a completely reproduc-
tive assessment of platelet recovery following transfusion. 
Indeed, we chose to collect the last platelet count prior 
to transfusion, and the next morning’s resulting platelet 
count. So the time interval between both platelet counts, 
as well as the timing of the transfusion in between, is 
likely to impact the difference. In the same way, this ques-
tions the exhaustiveness of collection of bleeding events. 
Undoubtedly, grade 3 and 4 bleeding events were sig-
nificant enough to be reported in the charts, but grade 1 
and 2 events might have been inconsistently mentioned. 
Finally, although our results suggest that the depth of 
thrombocytopenia was not an accurate predictor of 
severe bleeding, the retrospective design of the study 
and the quite low number of patients who bled precluded 
developing a more comprehensive and reliable multivari-
ate predictive model of bleeding.
Conclusion
In accordance with recent expert recommenda-
tions, most prophylactic platelet transfusions were 
given using restrictive thresholds of 10–20  ×  109/L 
in critically ill cancer patients with hypoproliferative 
thrombocytopenia. As a matter of fact, the risk of ICU-
acquired severe bleeding appears hardly predictable 
with the depth of thrombocytopenia. Further prospec-
tive interventional studies are needed in order to reli-
ably identify safe thresholds for platelet transfusion in 
critically patients with hypoproliferative thrombocyto-
penia in relation with the complex prediction of severe 
bleeding.
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